DEXA Bone Density: Medication-Driven Changes, Normal Ranges, and Optimal Targets

What Is a DEXA Scan and What Does It Measure?

DEXA is the reference-standard imaging test for bone mineral density (BMD). The machine passes two low-dose X-ray beams through bone, calculates areal BMD in g/cm², and then converts that number into two standard scores: the T-score (compared with a peak young-adult reference population) and the Z-score (compared with age- and sex-matched peers). Both the lumbar spine (L1-L4) and the proximal femur (total hip and femoral neck) are measured at every study.

T-Score vs. Z-Score: Which One Drives Treatment Decisions?

The T-score drives fracture-risk classification and prescribing decisions in postmenopausal women and men aged 50 and older. The World Health Organization 1994 criteria define three categories based on T-score alone: normal (T-score at or above -1.0), osteopenia (T-score -1.0 to -2.5), and osteoporosis (T-score at or below -2.5) [1]. A T-score of -2.5 corresponds to a BMD roughly 2.5 standard deviations below the mean for a healthy 30-year-old.

The Z-score is more meaningful in premenopausal women, men under 50, and children. A Z-score below -2.0 is defined as "below the expected range for age" by the International Society for Clinical Densitometry (ISCD) and should trigger evaluation for secondary causes of bone loss [2].

Precision, Reproducibility, and the Least Significant Change

DEXA machines have a coefficient of variation of roughly 1 to 1.5 percent at the lumbar spine. The ISCD defines the least significant change (LSC) as approximately 2.8 to 4.2 percent depending on the site and operator [2]. A change in BMD between two scans must exceed the LSC before a clinician can call it a real change rather than measurement noise. This is why most guidelines recommend waiting 1 to 2 years between monitoring scans rather than repeating at 6 months.

DEXA Bone Density Normal Range and Optimal Targets

The WHO threshold defines the floor for normal, not the goal. A T-score of -1.0 is technically "normal," but a T-score of 0.0 (exactly average for a 30-year-old) or above carries meaningfully lower fracture risk.

What Counts as Optimal in Longevity Medicine?

In longevity-focused clinical practice, many practitioners now aim for a lumbar spine T-score of 0.0 or higher and a femoral neck T-score of -0.5 or higher. The rationale is straightforward. Each standard deviation decline in femoral neck BMD multiplies hip fracture risk by approximately 2.6-fold in women and 2.0-fold in men, as shown in the Study of Osteoporotic Fractures (N=9,516) [3]. Holding BMD close to the peak-adult mean rather than merely above the osteoporosis cut point reduces lifetime fracture probability.

The ISCD 2023 Official Positions confirm that the primary clinical goal on pharmacotherapy is "fracture prevention, not a specific T-score target," but they also note that most fracture reduction benefit in bisphosphonate trials occurred in patients who reached a T-score above -2.5 at the lumbar spine [2].

Age-Related Decline and What to Expect Without Intervention

Women lose approximately 1 to 2 percent of lumbar spine BMD per year in the first three to five years after menopause due to estrogen withdrawal [4]. Men lose roughly 0.5 to 1 percent per year from their mid-30s onward. By age 75, one in three women and one in five men in the United States meet DEXA criteria for osteoporosis [5]. Without any intervention, a woman entering menopause at a T-score of -1.5 could reach the -2.5 threshold within five to ten years.

DEXA Screening: Who Gets Scanned and When?

The U.S. Preventive Services Task Force (USPSTF) recommends DEXA screening for all women aged 65 and older, and for younger postmenopausal women whose 10-year fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors [6]. The USPSTF concludes that "evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men" as of its 2018 update [6].

FRAX and Treatment Thresholds

The FRAX tool (WHO Fracture Risk Assessment Tool) integrates T-score, age, sex, body weight, prior fracture history, parental hip fracture, glucocorticoid use, smoking, alcohol, rheumatoid arthritis, and secondary osteoporosis into a 10-year absolute fracture probability. The National Osteoporosis Foundation (NOF) and the American Association of Clinical Endocrinology (AACE) recommend pharmacotherapy when the 10-year probability of a major osteoporotic fracture reaches 20 percent or more, or hip fracture reaches 3 percent or more [7]. These thresholds exist regardless of whether the T-score alone meets -2.5.

When to Scan Earlier Than Age 65

Earlier screening applies to women with any of the following: history of fragility fracture after age 40, glucocorticoid use of 5 mg/day prednisone-equivalent for 3 months or longer, premature menopause (before age 45), malabsorption syndromes (celiac, Crohn's), or prolonged amenorrhea. Men with hypogonadism, androgen-deprivation therapy, or chronic glucocorticoid use should also be scanned regardless of age [7].

Medication-Driven Changes in DEXA Bone Density

Four drug classes produce the largest, best-documented changes in DEXA T-score: bisphosphonates, parathyroid hormone analogues, sclerostin inhibitors, and hormone replacement therapy. Each works through a distinct mechanism and produces a different magnitude and speed of BMD gain.

Bisphosphonates: Alendronate, Risedronate, Zoledronate

Bisphosphonates inhibit osteoclast-mediated bone resorption. Alendronate 70 mg once weekly is the most prescribed agent in the United States. In the Fracture Intervention Trial (FIT, N=2,027), women with low femoral neck BMD who received alendronate for 3 years experienced a 7.1 percent increase in lumbar spine BMD and a 5.4 percent increase in femoral neck BMD versus baseline, compared with 0.4 percent and 0.9 percent in the placebo group [8]. Vertebral fracture risk fell by 47 percent (relative risk reduction) [8].

Zoledronic acid 5 mg intravenous once yearly performed similarly in the HORIZON Key Fracture Trial (N=7,765): lumbar spine BMD rose by 6.7 percent and femoral neck by 5.1 percent at 3 years, with a 70 percent reduction in morphometric vertebral fractures versus placebo [9].

Risedronate 35 mg weekly produces lumbar spine gains of approximately 5 to 6 percent over 3 years. The VERT-MN trial (N=1,628) showed a 49 percent relative reduction in new vertebral fractures at 3 years [10].

Parathyroid Hormone Analogues: Teriparatide and Abaloparatide

Teriparatide (recombinant PTH 1-34, 20 mcg subcutaneous daily) is an anabolic agent. It stimulates osteoblast activity rather than suppressing osteoclasts. In the key teriparatide fracture prevention trial (N=1,637), women treated for a median of 21 months gained 9.7 percent in lumbar spine BMD and 2.6 percent at the femoral neck, versus losses of 0.7 percent and 1.8 percent on placebo [11]. New vertebral fractures fell by 65 percent [11].

Abaloparatide 80 mcg daily (ACTIVE trial, N=2,463) produced a 11.2 percent lumbar spine BMD gain over 18 months, with a 43 percent reduction in new vertebral fracture risk versus placebo (P<0.001) [12].

Both agents carry a boxed warning for osteosarcoma risk in patients with a prior history of skeletal radiation or Paget's disease. Cumulative duration of teriparatide use is capped at 24 months lifetime.

Romosozumab: Sclerostin Inhibition

Romosozumab (Evenity, 210 mg subcutaneous monthly) blocks sclerostin, a protein that normally inhibits osteoblast activity. The dual mechanism both stimulates bone formation and suppresses resorption. In the ARCH trial (N=4,093), postmenopausal women with osteoporosis and prior vertebral fracture received romosozumab for 12 months followed by alendronate. At 12 months, lumbar spine BMD increased by 13.3 percent versus a 5.9 percent gain in the alendronate-only group [13]. The risk of a new vertebral fracture at 24 months was 48 percent lower in the romosozumab-to-alendronate sequence versus alendronate alone [13].

Romosozumab carries a boxed warning for cardiovascular events (myocardial infarction and stroke) and is contraindicated in patients with a prior MI or stroke within the past year [13].

Hormone Replacement Therapy and DEXA

Estrogen directly suppresses osteoclast activity. In the Women's Health Initiative (WHI) bone substudy (N=16,608 for the combined arm), conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg increased total hip BMD by 3.7 percent and spine BMD by 4.5 percent over 3 years compared with placebo [14]. The full WHI trial showed a 34 percent reduction in hip fracture and a 35 percent reduction in vertebral fracture in the combined HRT arm [14].

Estrogen-alone therapy in the WHI (N=10,739 hysterectomized women) produced nearly identical skeletal effects. More recently, observational data and smaller RCTs confirm that lower doses and transdermal routes also preserve BMD meaningfully, though the head-to-head fracture-endpoint data come primarily from the oral conjugated estrogen studies.

Testosterone Replacement and Bone in Men

Testosterone replacement therapy (TRT) in hypogonadal men raises BMD primarily through aromatization to estradiol. The Testosterone Trials (TTrials, N=790 men aged 65 and older with low testosterone), as reported in the New England Journal of Medicine in 2016, showed that testosterone gel for 1 year increased lumbar spine BMD by 7.5 percent and femoral neck BMD by 4.3 percent versus placebo [15]. These gains were mediated largely by estradiol levels, since co-administration of an aromatase inhibitor attenuated the skeletal benefit [15].

Monitoring DEXA on Pharmacotherapy

Once a patient begins pharmacotherapy, the ISCD recommends repeat DEXA scanning every 1 to 2 years until BMD is stable, then every 2 years [2]. "Stable" is defined as two consecutive scans where the change does not exceed the machine-specific LSC.

What to Expect at Each Follow-Up Scan

On alendronate, patients can expect roughly 3 to 4 percent lumbar spine gain in the first year and a tapering rate thereafter. Teriparatide produces faster early gains, with about 6 percent in the first year. Romosozumab delivers most of its anabolic benefit within the first 6 to 9 months of treatment, which is why the approved course is limited to 12 monthly injections followed by antiresorptive therapy.

Patients should be told that modest BMD gains on DEXA underestimate the actual fracture risk reduction. Bisphosphonates reduce vertebral fracture risk by 40 to 50 percent with spine BMD gains of only 5 to 8 percent. The discrepancy is partly explained by improvements in bone microarchitecture and mineralization that DEXA does not directly measure.

Drug Holidays and Residual Effect

For bisphosphonates, a drug holiday of 2 to 5 years may be appropriate after 5 years of oral therapy or 3 years of intravenous zoledronate in lower-risk patients, because bisphosphonates are retained in bone mineral for years after discontinuation [7]. The FLEX extension trial (N=1,099) showed that women who continued alendronate for 10 years had a lower risk of clinical vertebral fracture than those who stopped at 5 years, though hip fracture rates were similar [16]. Decisions about holiday duration should be based on a repeat FRAX calculation and site-specific BMD at the time of discontinuation.

Secondary Causes of Bone Loss That Affect Monitoring

Before attributing a continued decline in BMD to inadequate drug response, clinicians should rule out secondary causes: vitamin D deficiency (25-OH vitamin D <30 ng/mL), calcium intake below 1,000 to 1,200 mg/day, hyperparathyroidism, hyperthyroidism, celiac disease, renal osteodystrophy, and malabsorption. The Endocrine Society notes that undiagnosed secondary causes account for 30 to 50 percent of apparent treatment failures in postmenopausal osteoporosis [17].

Calcium, Vitamin D, and Lifestyle: The Baseline That Drugs Build On

No pharmacotherapy works optimally without adequate calcium and vitamin D. The National Academy of Medicine recommends 1,000 mg/day elemental calcium for adults aged 19 to 50 and 1,200 mg/day for women over 50 and all adults over 70 [18]. Vitamin D recommendations are 600 to 800 IU/day for most adults, with many endocrinologists targeting serum 25-OH vitamin D above 30 ng/mL in patients being treated for osteoporosis [17].

Resistance training and weight-bearing exercise produce a measurable osteogenic stimulus. A meta-analysis of 11 randomized trials (N=1,081) found that combined resistance plus impact exercise increased lumbar spine BMD by 1.5 percent over 6 to 12 months [19]. That gain is modest compared with pharmacotherapy, but it compounds annually and carries benefits for muscle mass and fall prevention that DEXA does not capture.

Smoking reduces bone formation and accelerates menopause by roughly 2 years, producing earlier estrogen withdrawal. Heavy alcohol use (more than 3 units/day) impairs osteoblast function. Both are independent FRAX risk factors and should be addressed alongside pharmacotherapy.

Practical Clinical Decision Flow for DEXA-Guided Prescribing

A T-score of -2.5 or lower at any site triggers pharmacotherapy per every major guideline. A T-score between -1.0 and -2.5 (osteopenia) requires the FRAX calculation to determine whether the 10-year fracture probability crosses the treatment threshold. For a 60-year-old woman with a femoral neck T-score of -2.0, prior wrist fracture, and a mother with hip fracture, FRAX often exceeds 20 percent major fracture probability even without a T-score at -2.5.

First-line therapy in most guidelines is an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) due to cost, long-term safety data, and oral convenience. Intravenous zoledronate 5 mg annually is preferred when gastrointestinal tolerability is a concern or adherence to oral weekly dosing is poor [7]. Anabolic-first sequencing (teriparatide or romosozumab followed by an antiresorptive) is reserved for patients with T-scores below -3.0, multiple prior fractures, or very high 10-year fracture probability, because transitioning from anabolic to antiresorptive consolidates the BMD gains and protects against the reversal that occurs if anabolic therapy is discontinued without a follow-on agent.

The Endocrine Society 2019 clinical practice guideline on osteoporosis states: "For most postmenopausal women with osteoporosis, bisphosphonate therapy is the preferred initial treatment due to its efficacy, safety record, and cost-effectiveness" [17].

The American Association of Clinical Endocrinology (AACE) 2020 guidelines add: "Patients at very high risk (T-score below -3.0, prior hip or vertebral fracture, or FRAX 10-year hip fracture probability above 4.5%) should be considered for anabolic-first therapy" [7].